10/4/2010

A head-to-head study found that injectable cancer drug Avastin and standard eye medicine Lucentis, both developed by Genentech, are equally effective in treating wet age-related macular degeneration. The finding might pave the way for FDA approval of Avastin for the condition.

Related Summaries